BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22032883)

  • 1. Pegylation of DDA:TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responses.
    Kaur R; Bramwell VW; Kirby DJ; Perrie Y
    J Control Release; 2012 Feb; 158(1):72-7. PubMed ID: 22032883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Manipulation of the surface pegylation in combination with reduced vesicle size of cationic liposomal adjuvants modifies their clearance kinetics from the injection site, and the rate and type of T cell response.
    Kaur R; Bramwell VW; Kirby DJ; Perrie Y
    J Control Release; 2012 Dec; 164(3):331-7. PubMed ID: 22800572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen.
    Henriksen-Lacey M; Bramwell VW; Christensen D; Agger EM; Andersen P; Perrie Y
    J Control Release; 2010 Mar; 142(2):180-6. PubMed ID: 19874860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production.
    Henriksen-Lacey M; Devitt A; Perrie Y
    J Control Release; 2011 Sep; 154(2):131-7. PubMed ID: 21640145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01.
    Wilkinson A; Lattmann E; Roces CB; Pedersen GK; Christensen D; Perrie Y
    J Control Release; 2018 Dec; 291():1-10. PubMed ID: 30291987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog.
    Christensen D; Henriksen-Lacey M; Kamath AT; Lindenstrøm T; Korsholm KS; Christensen JP; Rochat AF; Lambert PH; Andersen P; Siegrist CA; Perrie Y; Agger EM
    J Control Release; 2012 Jun; 160(3):468-76. PubMed ID: 22709414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses.
    Davidsen J; Rosenkrands I; Christensen D; Vangala A; Kirby D; Perrie Y; Agger EM; Andersen P
    Biochim Biophys Acta; 2005 Dec; 1718(1-2):22-31. PubMed ID: 16321607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Th1 immune responses can be modulated by varying dimethyldioctadecylammonium and distearoyl-sn-glycero-3-phosphocholine content in liposomal adjuvants.
    Hussain MJ; Wilkinson A; Bramwell VW; Christensen D; Perrie Y
    J Pharm Pharmacol; 2014 Mar; 66(3):358-66. PubMed ID: 24251796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: characterisation, environmental scanning electron microscopy and immunisation studies in mice.
    Vangala A; Kirby D; Rosenkrands I; Agger EM; Andersen P; Perrie Y
    J Pharm Pharmacol; 2006 Jun; 58(6):787-99. PubMed ID: 16734980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of incorporating cholesterol into DDA:TDB liposomal adjuvants on bilayer properties, biodistribution, and immune responses.
    Kaur R; Henriksen-Lacey M; Wilkhu J; Devitt A; Christensen D; Perrie Y
    Mol Pharm; 2014 Jan; 11(1):197-207. PubMed ID: 24171445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subunit vaccines: distearoylphosphatidylcholine-based liposomes entrapping antigen offer a neutral alternative to dimethyldioctadecylammonium-based cationic liposomes as an adjuvant delivery system.
    McNeil SE; Rosenkrands I; Agger EM; Andersen P; Perrie Y
    J Pharm Sci; 2011 May; 100(5):1856-65. PubMed ID: 21374619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method.
    Nordly P; Rose F; Christensen D; Nielsen HM; Andersen P; Agger EM; Foged C
    J Control Release; 2011 Mar; 150(3):307-17. PubMed ID: 21111765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3β-[N-(N',N'-Dimethylaminoethane)carbomyl] cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium propane (DOTAP): prolonged liposome retention mediates stronger Th1 responses.
    Henriksen-Lacey M; Christensen D; Bramwell VW; Lindenstrøm T; Agger EM; Andersen P; Perrie Y
    Mol Pharm; 2011 Feb; 8(1):153-61. PubMed ID: 21117621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case-study investigating the physicochemical characteristics that dictate the function of a liposomal adjuvant.
    Perrie Y; Kastner E; Kaur R; Wilkinson A; Ingham AJ
    Hum Vaccin Immunother; 2013 Jun; 9(6):1374-81. PubMed ID: 23584249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of trehalose 6,6'-diester (TDX) chain length on the physicochemical and immunopotentiating properties of DDA/TDX liposomes.
    Kallerup RS; Madsen CM; Schiøth ML; Franzyk H; Rose F; Christensen D; Korsholm KS; Foged C
    Eur J Pharm Biopharm; 2015 Feb; 90():80-9. PubMed ID: 25445301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adsorption of protein antigen to the cationic liposome adjuvant CAF®01 is required for induction of Th1 and Th17 responses but not for antibody induction.
    Wørzner K; Hvannastein J; Schmidt ST; Foged C; Rosenkrands I; Pedersen GK; Christensen D
    Eur J Pharm Biopharm; 2021 Aug; 165():293-305. PubMed ID: 34044110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration.
    Schmidt ST; Olsen CL; Franzyk H; Wørzner K; Korsholm KS; Rades T; Andersen P; Foged C; Christensen D
    Eur J Pharm Biopharm; 2019 Jul; 140():29-39. PubMed ID: 31055066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PEGylated cationic liposomes robustly augment vaccine-induced immune responses: Role of lymphatic trafficking and biodistribution.
    Zhuang Y; Ma Y; Wang C; Hai L; Yan C; Zhang Y; Liu F; Cai L
    J Control Release; 2012 Apr; 159(1):135-42. PubMed ID: 22226776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Designing CAF-adjuvanted dry powder vaccines: spray drying preserves the adjuvant activity of CAF01.
    Ingvarsson PT; Schmidt ST; Christensen D; Larsen NB; Hinrichs WL; Andersen P; Rantanen J; Nielsen HM; Yang M; Foged C
    J Control Release; 2013 May; 167(3):256-64. PubMed ID: 23415813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of the effect of BCG vaccine against tuberculosis using DDA/TDB liposomes containing a fusion protein of HspX, PPE44, and EsxV.
    Mansury D; Ghazvini K; Amel Jamehdar S; Badiee A; Tafaghodi M; Nikpoor AR; Amini Y; Jaafari MR
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):370-377. PubMed ID: 30691310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.